Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Antonin Lamazière is active.

Publication


Featured researches published by Antonin Lamazière.


Nature Communications | 2017

Dendrogenin A drives LXR to trigger lethal autophagy in cancers

Gregory Segala; Marion David; Philippe de Medina; Mathias C. Poirot; Nizar Serhan; François Vergez; Aurélie Mougel; Estelle Saland; Kevin Carayon; Julie Leignadier; Nicolas Caron; Maud Voisin; Julia Cherier; Laetitia Ligat; Frédéric Lopez; Emmanuel Noguer; Arnaud Rives; Bruno Payré; Talal Al Saati; Antonin Lamazière; Gaëtan Despres; Jean-Marc A. Lobaccaro; Silvère Baron; Cécile Demur; Fabienne De Toni; Clément Larrue; Héléna Boutzen; Fabienne Thomas; Jean-Emmanuel Sarry; Marie Tosolini

Dendrogenin A (DDA) is a newly discovered cholesterol metabolite with tumor suppressor properties. Here, we explored its efficacy and mechanism of cell death in melanoma and acute myeloid leukemia (AML). We found that DDA induced lethal autophagy in vitro and in vivo, including primary AML patient samples, independently of melanoma Braf status or AML molecular and cytogenetic classifications. DDA is a partial agonist on liver-X-receptor (LXR) increasing Nur77, Nor1, and LC3 expression leading to autolysosome formation. Moreover, DDA inhibited the cholesterol biosynthesizing enzyme 3β-hydroxysterol-Δ8,7-isomerase (D8D7I) leading to sterol accumulation and cooperating in autophagy induction. This mechanism of death was not observed with other LXR ligands or D8D7I inhibitors establishing DDA selectivity. The potent anti-tumor activity of DDA, its original mechanism of action and its low toxicity support its clinical evaluation. More generally, this study reveals that DDA can direct control a nuclear receptor to trigger lethal autophagy in cancers.Dendrogenin A, cholesterol metabolite, has tumor suppressive properties but the mechanisms are unknown. Here the authors show that Dendrogenin A can induce autophagy-mediated cell death in both melanoma and acute myeloid leukaemia.


Expert Opinion on Drug Discovery | 2014

How lipidomics provides new insight into drug discovery

Antonin Lamazière; Claude Wolf; Peter J. Quinn

Introduction: Automated lipidomic methods based on mass spectrometry (MS) are now proposed to screen a large variety of candidate drugs available that inhibit de novo lipid synthesis and replace tedious methods based on radiotracer incorporation. A major new interest in inhibitors of de novo lipogenesis is their proapoptotic effect observed in cancerous cells. Areas covered: In this review, the authors focus on the screening methods of antilipogenic inhibitors targeting the synthesis of malonylCoA (carbonic anhydrase, acetylCoA carboxylase), palmitylCoA (fatty acid synthase condensing and thioesterase subunits) and monounsaturated fatty acids (Δ9-desaturase). The consequences of inhibition depend on how the pathway deviates above the blockade: accelerated mitochondrial fatty acid oxidation following the decreased malonylCoA level, accumulation of ketone bodies and increased cholesterol synthesis following the increased acetylCoA level. Side effects such as anorexia and skin defects may critically decrease therapeutic indices in the long term. The authors emphasize the need for assessment of toxicity in short-term treatments inducing proapoptotic effects observed in aggressive hormone-dependent malignancies. Expert opinion: The activity of lipogenesis inhibitors can be recognised in lipid profiles established by a combination of MS-based measurements and multivariate analysis processing hundreds of lipid molecular species. Because the method can be automated, it is suitable for screening large chemical libraries, with particular focus on anticancer activities.


Journal of the Endocrine Society | 2017

A Liquid Chromatography/Tandem Mass Spectometry Profile of 16 Serum Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of Congenital Adrenal Hyperplasia

Jean Fiet; Yves Le Bouc; Jérôme Guéchot; Nicolas Hélin; Marie-Anne Maubert; Dominique Farabos; Antonin Lamazière

Context: Congenital adrenal hyperplasia (CAH) due to steroid 21-hydroxylase deficiency (CAH21) is most often diagnosed by newborn screening. The classic parameter studied is 17-hydroxy-progesterone, but the positive predictive value for the diagnosis of CAH is low in full-term newborns and even lower in preterm newborns. Objective: To evaluate the diagnostic utility of simultaneously quantifying a large number of steroids by using liquid chromatography/tandem mass spectrometry (LC-MS/MS) from a small serum volume in patients with CAH, particularly during the neonatal period. Setting and participants: LC-MS/MS was applied to sera from patients with CAH who had a classic form (n = 48) and rare forms (n = 2) of 21-hydroxylase deficiency, normal preterm (n = 10) and normal full-term (n = 20) neonates, and young patients without CAH (non-CAH; n = 149) but with various other diseases (delayed or advanced puberty, hirsutism, pubarche, adrenarche, simple growth retardation). Methods: Sixteen steroids (glucocorticoids, mineralocorticoids, androgens, Δ5-steroids) were analyzed in 150 µL of serum by LC-MS/MS. Results: An LC-MS/MS serum steroid profile was developed and validated to provide a reliable etiologic diagnosis of CAH. The serum levels of 17OH-progesterone and 21 deoxycortisol in non-CAH are reported, along with the rarely assayed 21-deoxycorticorticosterone and 11β hydroxy Δ4-androstenedione, which will aid in the diagnosis of CAH21. In addition, serum levels of mineralocorticoids, androgens, and Δ5-steroids allowed investigation of other forms of CAH. Conclusion: This steroid LC-MS/MS approach on a small serum volume is well suited for pediatrics, particularly neonatal medical practice, to aid in the diagnosis and monitoring of various forms of CAH.


Frontiers in Molecular Neuroscience | 2017

Specific Physical Exercise Improves Energetic Metabolism in the Skeletal Muscle of Amyotrophic-Lateral- Sclerosis Mice

Céline Desseille; Séverine Deforges; Olivier Biondi; Léo Houdebine; Domenico D’amico; Antonin Lamazière; Cédric Caradeuc; Gildas Bertho; Gaelle Bruneteau; Laure Weill; Jean Bastin; Fatima Djouadi; François Salachas; Philippe Lopes; Christophe Chanoine; Charbel Massaad; Frédéric Charbonnier

Amyotrophic Lateral Sclerosis is an adult-onset neurodegenerative disease characterized by the specific loss of motor neurons, leading to muscle paralysis and death. Although the cellular mechanisms underlying amyotrophic lateral sclerosis (ALS)-induced toxicity for motor neurons remain poorly understood, growing evidence suggest a defective energetic metabolism in skeletal muscles participating in ALS-induced motor neuron death ultimately destabilizing neuromuscular junctions. In the present study, we report that a specific exercise paradigm, based on a high intensity and amplitude swimming exercise, significantly improves glucose metabolism in ALS mice. Using physiological tests and a biophysics approach based on nuclear magnetic resonance (NMR), we unexpectedly found that SOD1(G93A) ALS mice suffered from severe glucose intolerance, which was counteracted by high intensity swimming but not moderate intensity running exercise. Furthermore, swimming exercise restored the highly ALS-sensitive tibialis muscle through an autophagy-linked mechanism involving the expression of key glucose transporters and metabolic enzymes, including GLUT4 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Importantly, GLUT4 and GAPDH expression defects were also found in muscles from ALS patients. Moreover, we report that swimming exercise induced a triglyceride accumulation in ALS tibialis, likely resulting from an increase in the expression levels of lipid transporters and biosynthesis enzymes, notably DGAT1 and related proteins. All these data provide the first molecular basis for the differential effects of specific exercise type and intensity in ALS, calling for the use of physical exercise as an appropriate intervention to alleviate symptoms in this debilitating disease.


Archive | 2018

An Evaluation of Multivariate Data Analysis Models for Lipidomic Parameters from Patients with Metabolic Syndrome Undergoing Remedial Treatment

D. Farabos; Claude Wolf; R. Chapier; Antonin Lamazière; Peter J. Quinn

Multivariate data methods have been applied in analysis of parameters derived from patients with metabolic syndrome undergoing a remedial regime. In an example involving parameters derived from the fatty acid composition of serum lipids multivariate modeling is challenged to identify potential biomarkers for prediction during the intervention. Multivariate methods also reveal useful applications to monitor compliance to the prescribed exercise and diet regime, a critical feature in a lifestyle intervention conducted over a long time period.


Biochimie | 2018

CYP46A1 protects against NMDA-mediated excitotoxicity in Huntington's disease: Analysis of lipid raft content

Lydie Boussicault; Radhia Kacher; Antonin Lamazière; Peter Vanhoutte; Jocelyne Caboche; Sandrine Betuing; Marie-Claude Potier

Huntingtons Disease (HD) is an autosomal dominant neurodegenerative disease caused by abnormal polyglutamine expansion in huntingtin (mHtt) protein leading to degeneration of striatal neurons. Excitotoxicity, consecutive to overstimulation of N-methyl d-aspartate receptors (NMDARs) has a pivotal role in many neurological disorders including HD. Mutant Htt causes enhanced NMDA sensitivity, alteration of NMDAR expression and localization in neurons. Excitotoxic events initiate neuronal death in numerous ways, including activation of apoptotic cascades. Among the NMDAR subunits involved in glutamatergic-mediated excitotoxicity, GluN2B has been extensively reported. In addition to excitotoxicity, alteration of cholesterol metabolism has been observed in HD, with a decrease of cholesterol precursor synthesis along with an increase of cholesterol accumulation, which is deleterious for neurons. Expression of Cholesterol Hydroxylase enzyme, CYP46A1, which converts cholesterol into 24 S-hydroxycholesterol is down-regulated in HD. We found that CYP46A1 overexpression is beneficial in HD neurons and mouse model, but the mechanisms involved still remain unclear. In this study we addressed the effect of CYP46A1 on NMDAR-mediated excitotoxicity in HD primary neurons and its role in modulating cholesterol and localization of GLUN2B in lipid rafts. We showed that CYP46A1 is protective against NMDAR-mediated excitotoxicity in two different HD neuronal cell models. Cholesterol as well as GluN2B level in lipid raft, are significantly increased by mHtt. Despite a clear effect of CYP46A1 in reducing cholesterol content in lipid raft extracts from wild type neurons, CYP46A1 overexpression in HD neurons could not normalize the increased cholesterol levels in lipid rafts. This study highlights the beneficial role of CYP46A1 against NMDAR-mediated excitotoxicity and gives further insights into the cellular mechanisms underlying CYP46A1-mediated neuroprotection.


Alzheimers & Dementia | 2015

Hippocampal CYP46A1 overexpression is beneficial in rodent models of Alzheimer’s disease

Sandro Alves; Antonin Lamazière; Mickael Audrain; Jérôme Braudeau; Françoise Fouquet; Patrick Aubourg; Nathalie Cartier

for the gamma. Conclusions:Predicted treatment effects based on normal or chi-square distributions may show greater progression and less variability than those based on gamma distributions. While the results are similar between normal and chi-square distributions, the latter may be preferred on statistical and clinical grounds: 1) it has fewer parameters to evaluate; 2) it allows for a more realistic distribution of declines over time, where a few patients may fail or worsen more markedly than would be predicted by the former.


Diabetologia | 2014

Exosomes participate in the alteration of muscle homeostasis during lipid-induced insulin resistance in mice

Hala Aswad; Alexis Forterre; Oscar P. B. Wiklander; Guillaume Vial; Emmanuelle Danty-Berger; Audrey Jalabert; Antonin Lamazière; Sandra Pesenti; Catherine Ott; Karim Chikh; Samir El-Andaloussi; Hubert Vidal; Etienne Lefai; Jennifer Rieusset; Sophie Rome


Journal of Inherited Metabolic Disease | 2016

Antenatal manifestations of inborn errors of metabolism: biological diagnosis.

Christine Vianey-Saban; Cécile Acquaviva; David Cheillan; Sophie Collardeau-Frachon; Laurent Guibaud; Cécile Pagan; Magali Pettazzoni; Monique Piraud; Antonin Lamazière; Roseline Froissart


Transplantation | 2017

Intravenous Lipid Emulsion Containing 15% Fish Oil Provides a New Red Blood Cell Fatty Acids Profile

Olivier Goulet; C. Lambe; Cécile Talbotec; Catherine Poisson; A. Rocha; Martine Postaire; Rozenn Clément; Antonin Lamazière; Marie-Anne Maubert; Claude Wolff

Collaboration


Dive into the Antonin Lamazière's collaboration.

Top Co-Authors

Avatar

Marie-Anne Maubert

Centre national de la recherche scientifique

View shared research outputs
Top Co-Authors

Avatar

A. Rocha

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

C. Lambe

Necker-Enfants Malades Hospital

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Catherine Poisson

Necker-Enfants Malades Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge